CN102727749A - Medicine for treating aplastic anemia - Google Patents
Medicine for treating aplastic anemia Download PDFInfo
- Publication number
- CN102727749A CN102727749A CN2012102334559A CN201210233455A CN102727749A CN 102727749 A CN102727749 A CN 102727749A CN 2012102334559 A CN2012102334559 A CN 2012102334559A CN 201210233455 A CN201210233455 A CN 201210233455A CN 102727749 A CN102727749 A CN 102727749A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- aplastic anemia
- blood
- wind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000032467 Aplastic anaemia Diseases 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title description 7
- 241000545442 Radix Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 235000006533 astragalus Nutrition 0.000 abstract description 4
- 241000221079 Euphorbia <genus> Species 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 241000830535 Ligustrum lucidum Species 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 210000004233 talus Anatomy 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000785781 Flueggea suffruticosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000002607 hemopoietic effect Effects 0.000 description 7
- 239000009636 Huang Qi Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 241000382455 Angelica sinensis Species 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 2
- 206010040860 Skin haemorrhages Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 241001555026 Euphorbia humifusa Species 0.000 description 1
- 241001599881 Euphorbia maculata Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 101150072055 PAL1 gene Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 241000867909 Securinega Species 0.000 description 1
- 241000132346 Securinega suffruticosa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicine for treating aplastic anemia, which is used for solving the treatment problem of aplastic anemia. The medicine is characterized by being prepared from processing various traditional Chinese medicines, and comprises the active pharmaceutical ingredients in parts by weight: 6-10 parts of astragalus, 8-15 parts of polygonatum, 8-15 parts of glossy privet fruit, 6-10 parts of flueggea suffruticosa, 6-10 parts of ox horn bone, 8-15 parts of largehead atractylodes rhizome, 6-10 parts of angelica, 8-15 parts of herba cladostachvdis and 3-6 parts of humifuse euphorbia herb. Clinical experiments show that the medicine for treating aplastic anemia has the characteristics of good curative effect and higher safety, and is worth being clinically applied and popularized.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to treat the medicine of aplastic anemia.
Background technology
(aplastic anemia is to reduce or a kind of anemia due to the obstacle takes place because of hemopoietic function of bone marrow AA) to aplastic anemia, is called for short " aplastic anemia ".Mainly show as hemopoietic hypofunction of marrow, pancytopenia and anemia, hemorrhage, infection syndrome.The anxious weight that relaxes the state of an illness according to onset can be divided into acute and chronic two kinds.The characteristics of acute are, from the beginning of anemia and not obvious, be first symptom with hemorrhage, infection, hyperpyrexia often, but disease progression are fast, and serious anemia promptly takes place rapidly soon: hemorrhage serious and extensive, and not only skin, mucosa and retinal hemorrhage, and often with visceral hemorrhage; Infection is more common in around oral cavity, pharynx, skin and the anus, and the hyperpyrexia that is caused by pneumonia, septicemia etc.; The course of disease is through dangerous, and the patient is everlasting in a short time because of infection or visceral hemorrhage death.The chronic type onset is slow, and except that the chronic progressive external anemia was arranged, often with skin and mucosal bleeding, severe patient was often with infecting and heating.The rare spontaneous recovery person of aplastic anemia in case make a definite diagnosis, answers active treatment.The treatment of aplastic anemia mainly is supporting treatment, short hemopoietic and bone marrow transplantation, and so-called supporting treatment mainly is that infusion erythrocyte and platelet are to keep cytometry.And blood transfusion causes blood transfusion property hemachromatosis easily repeatedly, and only uses hemopoietic growth factors such as G-CSF, EPO to the short hemopoietic treatment of aplastic anemia patient row, clinical no remarkable result.
Summary of the invention
Technical assignment of the present invention is the deficiency to above prior art, and the medicine of the sure treatment aplastic anemia of a kind of curative effect is provided.
The technical scheme that the present invention solves its technical problem is: a kind of medicine of treating aplastic anemia, it is characterized in that processing by plurality of Chinese, and its composition of raw materials and weight proportion are: 6 ~ 10 parts of the Radixs Astragali; 8 ~ 15 parts of Rhizoma Polygonatis, 8 ~ 15 parts of Fructus Ligustri Lucidi, 6 ~ 10 parts of Cacumen Securinegae Suffruticosaes; 6 ~ 10 parts on the Cornu Bovis seu Bubali cheek, 8 ~ 15 parts of the Rhizoma Atractylodis Macrocephalaes, 6 ~ 10 parts of Radix Angelicae Sinensis; 8 ~ 15 parts of nine layers of wind, 3 ~ 6 parts of Herba Euphorbiae Humifusaes.
Its optimum weight proportioning is: 8 parts of the Radixs Astragali, 10 parts of Rhizoma Polygonatis, 10 parts of Fructus Ligustri Lucidi, 8 parts of Cacumen Securinegae Suffruticosaes, 8 parts on the Cornu Bovis seu Bubali cheek, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Radix Angelicae Sinensis, 10 parts of nine layers of wind, 5 parts of Herba Euphorbiae Humifusaes.
Wherein said: the Radix Astragali is the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao or Radix Astragali Astragalus membranaceus (Fisch.) Bge..Nature and flavor are sweet, temperature.Return lung, spleen channel.But the merit invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.
Rhizoma Polygonati is the dry rhizome of liliaceous plant Yunnan Rhizoma Polygonati Polygonatum kingianum Coll.et Hemsl., Rhizoma Polygonati Polygonatum sibiricum Red. or Polygonatum cyrtonema Hua Polygonatum cyrtonema Hua.Nature and flavor are sweet, and are flat.Return spleen, lung, kidney channel.But the merit boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney tonifying.
Fructus Ligustri Lucidi is the dry mature fruit of Oleaceae plant Fructus Ligustri Lucidi Ligustrum lucidum Ait..Nature and flavor are sweet, bitter, cold.Return liver, kidney channel.But the merit nourishing the liver and kidney, black hair makes eye bright.
Cacumen Securinegae Suffruticosae is browse or the root of euphorbia plant Suffrutescent Securinega Twig Securinega suffruticosa (Pal1.) Rehd..Acrid in the mouth; Bitter; Slightly warm in nature.Return liver; Kidney; Spleen channel.But merit expelling wind and activating blood circulation; The strong muscle of kidney tonifying.
The Cornu Bovis seu Bubali cheek is Artiodactyla Bovidae cattle Bos taurus domesticus Gmelin, is used as medicine with the inner hard bone heart of Cornu Bovis seu Bubali.Nature and flavor are bitter, temperature.Merit can be stopped blooding.
The Rhizoma Atractylodis Macrocephalae is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz..Nature and flavor are bitter, sweet, temperature.Return spleen, stomach warp.But the merit invigorating the spleen and benefiting QI, the dampness diuretic, hidroschesis, antiabortive.
Radix Angelicae Sinensis is the dry root of umbelliferae angelica Angelica sinensis (Oliv.) Diels.Nature and flavor are sweet, hot, temperature.Return liver, the heart, spleen channel.Merit can be enriched blood and invigorated blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.
Nine layers of wind are the dry rattan of leguminous plant spatholobus suberectus Spatholobus suberectus Dunn.Nature and flavor are bitter, sweet, temperature.Return liver, kidney channel.Merit can be enriched blood, and invigorates blood circulation collateral dredging.
Herba Euphorbiae Humifusae is the dry herb of euphorbia plant Radix seu Caulis Parthenocissi tricuspidatae Euphorbia humifusa Willd. or Herba Euphorbiae supinae Euphorbia maculata L..Nature and flavor are hot, and are flat.Return liver, large intestine channel.But the merit heat-clearing and toxic substances removing, cooling blood for hemostasis.
Composition principle: the described aplastic anemia of modern medicine belongs to categories such as the traditional Chinese medical science " asthenia ", " blood disorder ", " warm ".The QI and blood of human body derives from each precise and tiny and essence in kidney of taste water.Insufficiency of the spleen biochemistry is had no right, and then marrow does not fill; The vital essence of suffering from a deficiency of the kidney loss, then the blood source is not filled.The spleen kidneys that adopt are ruled together more, but the medication of present clinical Chinese traditional treatment aplastic anemia biases toward the invigorating the spleen and replenishing QI hemopoietic more, but actual spleen kidney two thanks to is this; Multiple susceptible heresy (comprising poison heresy, radioactive substance, medicine etc.) is mark, and continuing then influences the heart, liver, QI and blood; Marrow further loses empty, and blood is capable unable, leads blood stasis.Control and work as strengthening spleen, tonifying kidney, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, rather than enriching blood simply.The present invention adopts Radix Astragali invigorating QI to consolidate the body surface resistance, Cacumen Securinegae Suffruticosae expelling wind and activating blood circulation, the strong muscle of kidney tonifying, this two medicine all be mend in interior drive in outside, reinforcement and elimination in combination; Rhizoma Polygonati boosting qi and nourishing yin, spleen invigorating lung moistening kidney tonifying, the Fructus Ligustri Lucidi nourishing the liver and kidney, Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, Chinese angelica blood supplementing is invigorated blood circulation, and helps the source of hemopoietic altogether; Nine layers of wind have the merit of invigorating blood circulation again in enriching blood, the Herba Euphorbiae Humifusae heat-clearing and toxic substances removing, and cooling blood for hemostasis, Cornu Bovis seu Bubali cheek hemostasis, this three blood medicine is opened the running that promotes haematogenous mechanism between entire, the phlegm and toxin stasis that also can prevent blood transfusion repeatedly to cause.
The specific embodiment
Below in conjunction with practical situation, specific embodiments of the invention elaborates.
Embodiment 1, the crude drug weight proportion: Radix Astragali 6g, Rhizoma Polygonati 8g, Fructus Ligustri Lucidi 8g, Cacumen Securinegae Suffruticosae 6g, Cornu Bovis seu Bubali cheek 6g, Rhizoma Atractylodis Macrocephalae 8g, Radix Angelicae Sinensis 6g, nine layers of wind 8g, Herba Euphorbiae Humifusae 3g.
Embodiment 2, the crude drug weight proportion: Radix Astragali 10g, Rhizoma Polygonati 15g, Fructus Ligustri Lucidi 15g, Cacumen Securinegae Suffruticosae 10g, Cornu Bovis seu Bubali cheek 10g, Rhizoma Atractylodis Macrocephalae 15g, Radix Angelicae Sinensis 10g, nine layers of wind 15g, Herba Euphorbiae Humifusae 6g.
Embodiment 3, the crude drug weight proportion: Radix Astragali 8g, Rhizoma Polygonati 10g, Fructus Ligustri Lucidi 10g, Cacumen Securinegae Suffruticosae 8g, Cornu Bovis seu Bubali cheek 8g, Rhizoma Atractylodis Macrocephalae 10g, Radix Angelicae Sinensis 8g, nine layers of wind 10g, Herba Euphorbiae Humifusae 5g.
During use, with Chinese medicine astragalus of the present invention, Rhizoma Polygonati, Fructus Ligustri Lucidi, Cacumen Securinegae Suffruticosae, the Cornu Bovis seu Bubali cheek, the Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Herba Euphorbiae Humifusae and nine layers of wind decocte with water twice, merging filtrate divides and sooner or later takes.
Effective combination of said medicine is coordinated mutually, can effectively reach the purpose of treatment aplastic anemia, and side effect is less.The above results is that clinical data proves that fully interrelated data is following, wherein studies drug use and is the crude drug weight proportion among the embodiment 3.
1 object and method.
1.1 object: the CAA patient that all cases all derive from July, 2010～2011 year December hematology outpatient service, are in hospital, totally 82 examples.
1.2 method.
1.2.1 divide into groups: 42 examples are organized in treatment, male's 24 examples wherein, women's 18 examples, 15～69 years old age, average (36.5 ± 14.7) year; Matched group 40 examples, male's 25 examples wherein, women's 15 examples, 12～70 years old age, average (37.2 ± 15.5) year.Physical data such as two groups of patient's sexes, age are no difference of science of statistics relatively.
1.2.2 Therapeutic Method: the oral stanozolol sheet of matched group (Pharmaceutical Group Co.,Ltd of Nanning Baihui, the accurate word H45020728 of traditional Chinese medicines) treatment, each 2 ~ 4mg, 3 times/d.The treatment group adds the embodiment of the invention 3 gained Chinese medicine decoction, 2 times/d on the matched group basis.Be 6 months two groups of courses of treatment.
1.2.3 observation index: two groups was 1 course of treatment with 6 months all; In the therapeutic process main observe the patient weak, breathe hard, ordinary circumstance such as hemorrhage; Blood transfusion number of times and time, liver function and hemogram (comprising leukocyte, hemoglobin, platelet count), bone marrow smear change, and estimate its curative effect.
1.2.4 curative effect determinate standard: with reference to the 4th standard that the aplastic anemia meeting is drafted in 1987, produce effects: anemia, bleeding disappeared hemoglobin male 120g/L, women 100g/L, leukocyte 4.0 * 10
9/ L, platelet 80 * 10
9More than/the L, follow up a case by regular visits to 1 year no recidivist.Effectively: anemia, bleeding disappear hemoglobin male 120g/L, women 100g/L, leukocyte 3.5 * 10
9About/L, platelet has to a certain degree to be recovered, and follows up a case by regular visits to 3 months stable disease or continues improvement person.Invalid: as can not to reach obvious progressive person through abundant treatment.
1.2.5 statistical analysis carries out statistical analysis with SPSS 13.0, < 0.05 expression has the significance meaning to P.
2 results.
2.1 the curative effect of two groups of cases relatively: see the following form, obvious effective rate and total effective rate treatment group obviously are superior to matched group (P < 0.05).
2.2 two groups of untoward reaction relatively: have 7 examples the transaminase to occur in matched group 40 examples and raise (17.5%), diseases (32.5%) such as acne, hirsutism, hoarseness in various degree appear in 13 examples.Do not occur above-mentioned untoward reaction in the treatment group, other systems inspection is not also found obviously unusual.
3. conclusion.
This result of study shows that the present invention treats the aplastic anemia determined curative effect, and adverse reaction rate is low, is worthy of promotion and application.
Claims (2)
1. a medicine of treating aplastic anemia is characterized in that being processed by plurality of Chinese, and its composition of raw materials and weight proportion are: 6 ~ 10 parts of the Radixs Astragali; 8 ~ 15 parts of Rhizoma Polygonatis, 8 ~ 15 parts of Fructus Ligustri Lucidi, 6 ~ 10 parts of Cacumen Securinegae Suffruticosaes; 6 ~ 10 parts on the Cornu Bovis seu Bubali cheek, 8 ~ 15 parts of the Rhizoma Atractylodis Macrocephalaes, 6 ~ 10 parts of Radix Angelicae Sinensis; 8 ~ 15 parts of nine layers of wind, 3 ~ 6 parts of Herba Euphorbiae Humifusaes.
2. a kind of medicine of treating aplastic anemia according to claim 1 is characterized in that its weight proportion is: 8 parts of the Radixs Astragali, 10 parts of Rhizoma Polygonatis, 8 parts of 10 parts of Cacumen Securinegae Suffruticosaes of Fructus Ligustri Lucidi, 8 parts on the Cornu Bovis seu Bubali cheek, 10 parts of the Rhizoma Atractylodis Macrocephalaes; 8 parts of Radix Angelicae Sinensis, 10 parts of nine layers of wind, 5 parts of Herba Euphorbiae Humifusaes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210233455 CN102727749B (en) | 2012-07-06 | 2012-07-06 | Medicine for treating aplastic anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210233455 CN102727749B (en) | 2012-07-06 | 2012-07-06 | Medicine for treating aplastic anemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102727749A true CN102727749A (en) | 2012-10-17 |
| CN102727749B CN102727749B (en) | 2013-10-16 |
Family
ID=46984513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210233455 Active CN102727749B (en) | 2012-07-06 | 2012-07-06 | Medicine for treating aplastic anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727749B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039039A (en) * | 2016-08-18 | 2016-10-26 | 李运斌 | Aplastic anemia treating traditional Chinese medicine preparation and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140605A (en) * | 1996-04-03 | 1997-01-22 | 崔连贵 | Channel tropism powder |
| CN101199748A (en) * | 2007-12-05 | 2008-06-18 | 李其孟 | Chinese medicine preparation for treating hematonosis |
| CN101254275A (en) * | 2008-03-10 | 2008-09-03 | 屈凤星 | Chinese medicine for curing aplastic anemia |
| CN101940612A (en) * | 2010-09-04 | 2011-01-12 | 荣成市新技术应用研究所 | Traditional Chinese medicine composite for treating anemia |
| CN102018826A (en) * | 2009-09-17 | 2011-04-20 | 杨建� | Traditional Chinese medicine for treating aplastic anemia |
-
2012
- 2012-07-06 CN CN 201210233455 patent/CN102727749B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140605A (en) * | 1996-04-03 | 1997-01-22 | 崔连贵 | Channel tropism powder |
| CN101199748A (en) * | 2007-12-05 | 2008-06-18 | 李其孟 | Chinese medicine preparation for treating hematonosis |
| CN101254275A (en) * | 2008-03-10 | 2008-09-03 | 屈凤星 | Chinese medicine for curing aplastic anemia |
| CN102018826A (en) * | 2009-09-17 | 2011-04-20 | 杨建� | Traditional Chinese medicine for treating aplastic anemia |
| CN101940612A (en) * | 2010-09-04 | 2011-01-12 | 荣成市新技术应用研究所 | Traditional Chinese medicine composite for treating anemia |
Non-Patent Citations (3)
| Title |
|---|
| 徐三文 等: "《中国血液病秘方全书》", 31 October 2003, 科学技术文献出版社 * |
| 徐功敕 等: "一叶萩碱治疗慢性再生障碍性贫血10例", 《华西医讯》 * |
| 隋殿军 等: "《当代名医医案医话选》", 31 August 1995, 吉林科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039039A (en) * | 2016-08-18 | 2016-10-26 | 李运斌 | Aplastic anemia treating traditional Chinese medicine preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102727749B (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101284121B (en) | Combination medicine for curing the hoary hair | |
| CN100536885C (en) | Medicine for treating phalacrosis and restoring hair | |
| CN100339114C (en) | Medicinal composition for treating alopecta and its prearation method | |
| CN103330805A (en) | Traditional Chinese medicine composition for treating menorrhagia | |
| CN101391033A (en) | Internal medicine for treating diabetes | |
| CN102727749B (en) | Medicine for treating aplastic anemia | |
| CN103251889A (en) | Traditional Chinese medicine composition for treating agalactia | |
| CN101199761B (en) | Drug for treating arteriosclerosis | |
| CN102512593B (en) | Traditional Chinese medicine preparation for treating aplastic anemia | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN104042839A (en) | Traditional Chinese medicine composition for treating tinea versicolor | |
| CN1149095C (en) | Chinese medicine for treating baby's congenital heart disease | |
| CN105288122A (en) | Drug for treating diabetes mellitus | |
| CN108567896A (en) | A kind of decoction of medicinal ingredients acting on the patients such as respiratory failure | |
| CN111514237B (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof | |
| CN102579831A (en) | Immunotherapy of treating cancer through snuffing and steaming traditional Chinese medicine | |
| CN101953943A (en) | Traditional Chinese medicine for treating chronic aplastic anemia | |
| CN102698062A (en) | Chinese herbal medicine for treating hypotension | |
| CN102166303B (en) | Chinese medicinal composition for treating chronic atrophic gastritis | |
| CN102727806B (en) | Traditional Chinese medicine for treating aplastic anemia by tonifying qi | |
| CN106421512A (en) | Traditional Chinese medicine composition for curing constipation | |
| CN101537114A (en) | Chinese medicine for treating arrhythmia | |
| CN105395883A (en) | Traditional Chinese medicine for curing anemia | |
| CN103751607A (en) | Traditional Chinese medicine composition for the treatment of aplastic anemia | |
| CN1054048C (en) | Oral liquid for treatment of cancer and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU JIAQIANG Effective date: 20140916 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276826 RIZHAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140916 Address after: 226200 chemical industry park, Nantong, Jiangsu, Qidong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 276826 Rizhao People's Hospital, 126 Tai'an Road, Shandong, Rizhao City, China Patentee before: Liu Jiaqiang |